Back Back
HER2-Negative EBC Tool Update
As the Treatment of HER2-Negative Early Breast Cancer Evolves, So Does Our Corresponding Treatment Decision Support Tool

Released: October 11, 2023

Laura M. Spring
Laura M. Spring, MD
Activity Information

Activity

Progress
1
Course Completed
Continue
Key Takeaways
  • Abemaciclib, olaparib, and pembrolizumab are each approved in the adjuvant setting for patients with HER2-negative early breast cancer.  
  • A team of 5 experts in breast cancer has updated our HER2-negative early breast cancer interactive treatment decision support tool to assist you with clinical decision-making about adjuvant therapies in your practice today.

Interactive Decision Support Tool
The treatment landscape of HER2-negative early breast cancer is continually evolving, with recent data and FDA approvals supporting abemaciclib, olaparib, and pembrolizumab in the adjuvant setting for eligible patients. To aid in treatment decisions encompassing targeted therapy in the setting of HER2-negative early breast cancer, my colleagues and I have developed an Interactive Decision Support Tool that includes patients with high-risk disease and germline pathogenic variants in BRCA (Figure 1). This tool has been created, evaluated, and designed by 5 experts who treat patients with breast cancer. As a user of the tool, you can input key patient and disease characteristics to define a patient scenario.

Figure 1. Entering patient and disease characteristics into the tool.

After entering key patient and disease characteristics, you select your intended treatment choice. Then you will be shown the recommendations from all 5 experts for your individual set of characteristics, along with a link to additional information to consider (Figure 2).

Figure 2. Expert treatment recommendations.

When you have a patient in front of you, this tool will help inform the decision-making that needs to occur and the process you should consider in ultimately individualizing treatment for that person.

Additional Resource
For further information on key trials, expert perspectives, discussion, and more on the latest treatment options for early breast cancer, check out this program.

Your Thoughts?
What are your suggestions for our updated HER2-negative early breast cancer Interactive Decision Support Tool? Please answer the polling question and join the conversation by posting a comment in the discussion section.

Continue

Poll

1.

Which of the following topics in early breast cancer would you like to get more expert insight on?

Submit